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CLINICAL/SCIENTIFIC NOTES OPEN ACCESS
LGI1 encephalitis with squamous lung-cell
carcinoma: Resolution after tumor resection
Akash Virupakshaiah,MD,Marinos C. Dalakas, MD, Neeja Desai, MD, ScottMintzer, MD, and Jeffrey Ratliff, MD




Encephalitis with leucine-rich glioma-inactivated-1 (LGI1) immunoglobulin G (IgG) anti-
bodies classically presents with cognitive impairment and characteristic faciobrachial dystonic
seizures.1 In a murine model, human LGI1 IgG caused reduction of Kv1.1 channels and
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor receptors resulting in neuro-
nal hyperexcitability indicating probable pathogenicity of LGI1 antibodies.2 LGI1 autoimmu-
nity is associated with malignancy in less than 10% of cases, including small cell lung cancer,
prostate and colon cancer, squamous cell skin carcinoma, and neuroendocrine pancreatic
cancer.3,4 We present a case of LGI1 encephalitis only partially responsive to immunotherapy
with eventual complete resolution after resection of a squamous cell lung carcinoma.
Case report
A 78-year-old woman was seen for evaluation of worsening cognition and brief spasmodic
episodes affecting the arm and face. On examination, she had stereotyped episodes of gri-
macing and left arm posturing, without impairment of awareness, lasting 2–4 seconds,
consistent with faciobrachial seizures. She also had dysarthria, hypophonia, and mild left hand
bradykinesia. Her mental status examination showed impaired orientation to our clinic,
impairment in delayed recall, and working memory deficits in reversed spelling and serial
subtraction tasks.
A brain MRI showed an incidental CSF cyst on the anterior pole of the left lateral ventricle and
bilateral subcortical microvascular changes, but no signs of limbic encephalitis. The CSF was
normal with only mild protein elevation of 68 mg/dL and negative for JC virus and neuro-
syphilis. Continuous EEG monitoring demonstrated no EEG correlation with her dystonic
events. She was hyponatremic, with sodium concentrations ranging from 127–132 mmol/L.
Initial serologic testing was positive for antibodies to the voltage-gated potassium channel
(VGKC) complex (0.11 nmol/L), but the results did not indicate specific protein targets
(i.e., LGI1 or Caspr2). She was treated with high-dose IV immunoglobulin and methylpred-
nisolone, and levetiracetam and clonazepam, but with only partial improvement of her dystonic
seizures. She hadmoderate improvement in her cognitive functioning with partial improvement
in delayed recollection and working memory. Follow-up testing for antibody specificity within
the VGKC complex by a different laboratory was negative. However, 2 months later, repeated
serum tested at the same laboratory using cell-based assay was positive specifically for LGI1.
Sevenmonths after her initial presentation, a CT of the chest showed a right lung mass. Surgical
resection demonstrated a moderately differentiated squamous cell carcinoma. After surgery, she
had a complete resolution of faciobrachial dystonic seizures; her cognitive dysfunction also
resolved, both subjectively and on follow-up examination. All previously applied neurologic
therapies were discontinued. She had remained seizure free for over 1 year, through her most
recent follow-up.
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To explore the association of her squamous cell lung cancer with
encephalitis, we tested sections from her paraffin-embedded
tumor tissue for expression of LGI1 antigen. After deparaffini-
zation, rehydration, antigen retrieval, and blocking, as previously
described,5 the tissue sections were incubated overnight with a
commercial rabbit polyclonal antibody against LGI1/EPT
(Abcam 30868) 10 μg/mL diluted in 1:20 normal goat se-
rum, followed by rhodamine-conjugated goat anti-rabbit IgG.5
Strong staining of many tumor cells was observed (figure, A).
Incubation of tumor sections with the same rhodamine-
conjugated secondary antibody, omitting the primary anti-
LGI1, showed no staining of tumor cells (figure, B), confirming
the specificity of the reaction. Immunostaining with LGI1-
positive serum from an autoimmune patient with encephalitis
diluted at 1:50 also showed that LGI1 was expressed in many
tumor cells with a patchy membrane staining (not shown).
Discussion
We present an association of LGI1 autoimmune encephalitis
with squamous cell lung carcinoma with dramatic resolution
of all clinical phenomena after surgical resection. The case
broadens the spectrum of paraneoplastic association with
LGI1 encephalitis and demonstrates that the response to
immunotherapy can be insufficient.
Although initial testing for the antibody was negative, the
patient eventually tested positive for LGI1 antibodies
confirming previous reports that LGI1 antibodies may
initially show only seropositivity for antibodies to the
VGKC complex.6 The connection of the encephalitis to the
tumor was strengthened by finding that the tumor strongly
expressed LGI1 antigen, although it was unclear which
specific tumor cells express LGI1. A study of gene ex-
pression in oral squamous cell cancer has shown that LGI1
expression may be elevated in the surrounding mucosa of
early squamous cell tumors, perhaps reflecting a mecha-
nism of tumor suppression.7 The neurologic autoimmunity
developed in our patient likely represents a paraneoplastic
mechanism with cross-reactive autoimmunity triggered by
LGI1 antigen expression within the neoplastic or the sur-
rounding non-neoplastic tumor cells as supported by the
complete resolution of the patient’s symptoms after tumor
resection.
Although still rare, the association of the typical neurologic
phenotype of LGI1 encephalitis with cancer and the complete
clinical response to tumor resection suggests an increased
need to evaluate for malignancy in future cases, especially
when the initial clinical response to immunotherapy is
incomplete.
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Figure Immunohistochemical staining of tumor sections
for LGI1 (×40)
Deparaffinized sections from the patient’s tumor immunostained with a
commercial polyclonal anti-LGI1 antibody, followed by rhodamine-conju-
gated secondary antibody (A, top) or only with the same secondary antibody
omitting the anti-LGI1 serum (B, bottom). Many LGI1-positive cells (red) are
identifiedwithin the tumor (A); no tumor cells were stained, other than some
connective tissue or vessels with the rhodamine-conjugated secondary
antibody alone (B). LGI1 = Leucine-rich glioma-inactivated-1.
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